Autoantibody determination in the diagnosis of systemic lupus erythematosus

Scandinavian Journal of Immunology

Volumn 64, Issue 3, 2006, Pages 227-235

  Kurien, B T ^a   Scofield, R H ^a,b,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; HISTONE ANTIBODY; LA ANTIBODY; PROTEIN ANTIBODY; RIBOSOME PROTEIN; SM ANTIBODY;

ANTIBODY DETECTION; CLINICAL FEATURE; COUNTER IMMUNOELECTROPHORESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNODIFFUSION; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RIBONUCLEOPROTEINS, SMALL NUCLEAR;

EID: 33747030602     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01819.x     Document Type: Review

References (130)

1. Fatovic-Ferencic S, Holubar K. Early history and iconography of lupus erythematosus. Clin Dermatol 2004;22:100-4.
2. Cazenave A, Schedel HE. Abrégé pratique des maladies de la peau. Paris: Béchet Jeune, 1828:4-9, 384-410, 510-2.
3. Cazenave A, Schedel HE. Abrégé pratique des maladies de la peau (Troisième édition). Paris: Béchet Jeune, 1838:5-14, 413-37.
4. Holubar K, Fatovic-Ferencic S. 1902-2002: a hundred years later. Moriz Kaposi 1837-1902: a historical reappraisal. Wien klin Wochenschr 2001;113:885-93.
5. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8.
6. Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol 2005;23:470-9.
7. Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 2004;16:794-800. Review.
8. Rus VHA, Hochberg MC. Systemic lupus erythematosus. In: Silman AJHM, ed. Epidemiology of the Rheumatic Diseases, 2nd edn. Oxford, UK: Oxford University Press, 2001: 123-40.
9. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32.
10. Schur PH. General Symptomatology and Diagnosis of Systemic Lupus Erythematosus in Adults. http://www.uptodate.com/physicians/ rheumatology_primary.asp (last accessed July 21, 2006).
11. Gilboe IM, Husby G. Application of the 1982 revised criteria for the classification of systemic lupus erythematosus on a cohort of 346 Norwegian patients with connective tissue disease. Scand J Rheumatol 1999;28:81-7.
12. Gill JM, Quisel AM, Rocca PV, Walters DT. Diagnosis of systemic lupus erythematosus. Am Fam Physician 2003;68:2179-86.
13. Schifferli JA. Systemic lupus erythematosus - myths and dogma. Ther Umsch 2005;62:292-6.
14. Lewis KS. Systemic lupus erythematosus: the great masquerader. Nurse Pract 1984;9:13-22.
15. Harley JB, Scofield RH. Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology. J Clin Immunol 1991;11:297-316.
16. Tan EM, Cohen AS, Fries JF et al. The 1982 Revised Criteria for the Classification of SLE. Arthritis Rheum 1982;25:1271-7.
17. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
18. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-6.
19. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
20. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363:1544-6.
21. Marchini B, Dolcher MP, Sabbatini A, Klein G, Migliorini P. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases. J Autoimmun 1994;7:179-91.
22. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501-37. Review.
23. Croker JA, Kimberly RP. SLE: challenges and candidates in human disease. Trends Immunol 2005;26:580-6.
24. Kurien BT, Scofield RH. Protein blotting: a review. J Immunol Methods 2003;274:1-15.
25. Kurien BT, Scofield RH. Western blotting. Methods 2006;38:283-93.
26. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:249-69.
27. van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods 1991;140:181-9.
28. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997;40:1612-8.
29. Froelich CJ, Wallman J, Skosey JL, Teodorescu M. Clinical value of an integrated ELISA system for the detection of 6 autoantibodies (ssDNA, dsDNA, Sm, RNP/Sm, SSA, and SSB). J Rheumatol 1990;17:192-200.
30. Gardner GC, Kadel NJ. Ordering and interpreting rheumatologic laboratory tests. J Am Acad Orthop Surg 2003;11:60-7.
31. Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in 'healthy' individuals [see comments]. Arthritis Rheum 1997;40:1601-11.
32. Ruffatti A, Calligaro A, Del Ross T et al. Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics. J Clin Immunol 1990;10:300-3.
33. Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998;21:4-11.
34. Bohan A. Seronegative systemic lupus erythematosus. J Rheumatol 1979;6:534-40.
35. de Vlam K, De Keyser F, Verbruggen G et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993;11:393-7.
36. Wahren M, Ringertz NR, Petterson I. IgM and IgG subclass distribution of human anti-Ro/SSA 60 kDa autoantibodies. Scand J Immunol 1994;39:179-83.
37. Fritzler MJ, Miller BJ. Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. J Clin Lab Anal 1995;9:218-24.
38. Keech CL, Howarth S, Coates T, Rischmueller M, McCluskey J, Gordon TP. Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60 kDa Ro HEp-2 transfectants. Pathology 1996;28:54-7.
39. Keech CL, McCluskey J, Gordon TP. Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. Clin Immunol Immunopathol 1994;73:146-51.
40. Pollock W, Toh BH. Routine immunofluorescence detection of Ro/SS-A autoantibody using HEp-2 cells transfected with human 60 kDa Ro/SS-A. J Clin Pathol 1999;52:684-7.
41. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996;156:1421-5.
42. Wiik AS, Gordon TP, Kavanaugh AF et al. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum 2004;51:291-8.
43. Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:534-40.
44. Tan EM, Smolen JS, McDougal JS et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 2002;29:68-74.
45. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-8.
46. Eilat D. The measurement of anti-DNA reactivity in the sera of patients with SLE: theoretical and practical considerations. Autoimmunity 1989;3:299-6.
47. Isenberg DA, Dudeney C, Williams E et al. Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis 1987;46:448-56.
48. Kadlubowski M, Jackson M, Yap PL et al. Lack of specificity for antibodies to double stranded DNA found in four commercial kits. J Clin Pathol 1991;44:246-50.
49. Chuan MT, Wu YC, Ang ET et al. Clinical significance of anti-nDNA antibodies in ANA-positive systemic lupus erythematosus: comparison of the Farr radioimmunoassay and the Crithidia luciliae immunofluorescent technique. Chin J Microbiol Immunol 1985;18:15-24.
50. Okamura M, Kanayama Y, Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double-stranded and single-stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993;52:14-20.
51. Clough JD, Chang RK. Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus. J Clin Lab Anal 1990;4:268-73.
52. Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975;254:505-15.
53. Gripenberg M, Helve T. Anti-DNA antibodies of IgA class in patients with systemic lupus erythematosus. Rheumatol Int 1986;6:53-5.
54. Avina-Zubieta JA, Galindo-Rodriguez G, Kwan-Yeung L et al. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus 1995;4:370-4.
55. Ehrenstein MR, Swana M, Keeling D, Asherson R, Hughes GR, Isenberg DA. Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS). Br J Rheumatol 1993;32:362-5.
56. Albani S, Massa M, Viola S, Pellegrini G, Martini A. Antibody reactivity against single stranded DNA of various species in normal children and in children with diffuse connective tissue diseases. Autoimmunity 1990;8:77-80.
57. Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti- dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992;1:369-77.
58. James K, Meek G. Evaluation of commercial enzyme immunoassays compared to immunofluorescence and double diffusion for autoantibodies associated with autoimmune diseases. Am J Clin Pathol 1992;97:559-65.
59. Fisher-Smikle M, James OB. Diagnosis of systemic lupus erythematosus in Jamaica by Crithidia luciliae indirect immunofluorescence test. Trans R Soc Trop Med Hyg 1987;81:255-6.
60. Hodinka L, Meretey K, Jancso A et al. Antibodies to native DNA in connective tissue disease. A comparison of radioimmunoassay, counter immunoelectrophoresis and indirect immunofluorescence on Crithidia luciliae substrate. Arch Immunol Ther Exp 1979;27:641-6.
61. Rubin R, Josli F, Tan E. A solid-phase radioimmunoassay for antihistone antibodies in human sera: comparison with immunofluorescence. Scand J Immunol 1982;15:63-70.
62. Aitkaci A, Monier J, Mamelle N. Enzyme-linked immunosorbent assay for anti-histone antibodies and their presence in SLE sera. J Immunol Methods 1981;44:311-22.
63. Massa M, De Benedetti F, Pignatti P et al. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:219-25.
64. Rubin W, Waga S. Anti-histone antibodies in systemic lupus erythematosus. J Rheumatol 1997;14(Suppl. 3):118-26.
65. Molden D, Klipple G, Peebles C et al. IgM anti-histone H3 antibodies associated with undifferentiated connective tissue disease. Arthritis Rheum 1986;29:39-46.
66. Yamagata H, Harley JB, Reichlin M. Molecular properties of the Ro/SSA antigen and ELISA for quantitation of antibody. J Clin Invest 1984;74:625-33.
67. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18:337-58.
68. Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology (Oxford) 2005;44:975-82.
69. Kurien BT, Newland J, Paczkowski C, Moore KL, Scofield RH. Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen. Clin Exp Immunol 2000;120:209-17.
70. Gordon T, Mavrangelos C, McCluskey J. Restricted epitope recognition by precipitin-negative anti-La/SS-B positive sera. Arthritis Rheum 1992;35:663-6.
71. Garcia Lerma JG, Mendoza AZ, Ramos MJ et al. Evaluation of recombinant Ro/SSA, La/SSB, Sm, and U1 RNP autoantigens in clinical diagnosis [see comments]. J Clin Lab Anal 1995;9:52-8.
72. Maddison PJ, Skinner RP, Vlachoyiannopolous P et al. Antibodies to nRNP, Sm, Ro(SSA) and La(SSB) detected by ELISA: their specificity and interrelations in connective tissue disease sera. Clin Exp Immunol 1985;62:337-45.
73. Pan LT, Tin SK, Boey ML et al. The sensitivity and specificity of autoantibodies to the Sm antigen in the diagnosis of systemic lupus erythematosus. Ann Acad Med Singap 1998;27:21-3.
74. Sirota P, Firer M, Schild K et al. Increased anti-Sm antibodies in schizophrenic patients and their families. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:793-800.
75. Hoch SO, Eisenberg RA, Sharp GC. Diverse antibody recognition patterns of the multiple Sm-D antigen polypeptides. Clin Immunol 1999;92:203-8.
76. Jaekel HP, Klopsch T, Benkenstein B et al. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. J Autoimmun 2001;17:347-54.
77. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005;38:47-54.
78. Habets WJA, Hoet MH, Sillekens PTG et al. Detection of autoantibodies in a quantitative ELISA using recombinant ribonucleoprotein antigens. Clin Exp Immunol 1989;76:172-7.
79. Molden DP, Suzuki H, Nakamura RM. Assays for Sm and RNP antibodies: pitfalls and technical considerations. Diagn Immunol 1985;3:24-8.
80. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 2005;1050:217-28.
81. Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005;38:85-92.
82. Arnett FC, Reveille JD, Moutsopolous HM et al. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 1996;39:1833-9.
83. Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996;39:1483-90.
84. Watanabe T, Sato T, Uchiumi T et al. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody [see comments]. Lupus 1996;5:178-83.
85. Agius MA, Chan JW, Chung S et al. Role of antiribosomal P protein antibodies in the diagnosis of lupus isolated to the central nervous system. Arch Neurol 1997;54:862-4.
86. West SG, Emlen W, Wener MH et al. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
87. Iverson GL. Are antibodies to ribosomal P proteins a clinically useful predictor of neuropsychiatric manifestations in patients with systemic lupus erythematosus. Lupus 1996;5:634-5.
88. Press J, Palayew K, Laxer RM et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996;39:671-6.
89. Sato T, Uchiumi T, Ozawa T et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991;18:1681-4.
90. Baqi N, Moazami S, Singh A et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996;7:924-9.
91. Sullivan KE, Wisnieski JJ, Winkelstein JA et al. Serum complement determinations in patients with quiescent systemic lupus erythematosus. J Rheumatol 1996;23:2063-7.
92. Sjoholm AG, Martensson U, Sturfelt G. Serial analysis of autoantibody responses to the collagen-like region of C1q, collagen type II, and double-stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 1997;24:871-8.
93. Gunnarsson I, Ronnelid J, Huang YH et al. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997;36:32-7.
94. Siegret C, Daha M, Westedt ML et al. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementaemia, and dsDNA antibodies in SLE. J Rheumatol 1991;18:230-4.
95. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-7.
96. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50.
97. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
98. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev 2004;12:267-75.
99. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;24:215-8.
100. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
101. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
102. Craig WY. Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J Clin Lab Anal 1995;9:70-4.
103. Steinerova A, Stozicky F, Racek J, Tatzber F, Zima T, Setina R. Antibodies against oxidized LDL in infants. Clin Chem 2001;47:1137-8.
104. Vaarala O. Antibodies to oxidised LDL. Lupus 2000;9:202-5.
105. Matsuura E, Lopez LR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 2004;11:103-11.
106. Kurien BT, Scofield RH. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci 2003;73:1655-66.
107. Kurien BT, Scofield RH. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 2006;44:349-56.
108. Escalante A, Brey RL, Mitchell BDJ et al. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:559-65.
109. Ghirardello A, Doria A, Ruffatti A et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome {see comments}? Ann Rheum Dis 1994;53:140-2.
110. Gulko PS, Reveille JD, Koopman WJ et al. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993;20:1684-93.
111. Merkel PA, Chang Y, Pierangeli SS et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576-83.
112. Day HM, Thiagarajan P, Ahn C et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998;25:667-74.
113. Abu-Shakra M, Urowitz MB, Gladman DD et al. The significance of anticardiolipin antibodies in patients with lupus nephritis. Lupus 1996;5:70-3.
114. Bhandari S, Harnden P, Brownjohn AM et al. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. Q J Med 1998;91:401-9.
115. Tomer Y, Viegas OA, Swissa M, Koh SC, Shoenfeld Y. Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol 1996;14:275-80.
116. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46:2957-63.
117. Chan TM, Cheng IKP. A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;78:41-6.
118. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum 1995;38:633-7.
119. Saisoong S, Eiam-Ong S, Hanvivatvong O. Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol 2006;24:51-8.
120. Khan F, Siddiqui AA. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. Clin Chim Acta 2006 (Epub ahead of print).
121. Khan F, Ali R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol 2006;39:189-96.
122. Mansoor F, Ali A, Ali R. Binding of circulating SLE autoantibodies to oxygen free radical damaged chromatin. Autoimmunity 2005;38:431-8.
123. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20:539-50.
124. Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:513-7.
125. Becker GJ, Waldburger M, Hughes GR et al. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980;39:50-2.
126. Hind C, Ng SC, Feng PH. Serum C-reactive protein measurements in the detection of intercurrent infection in oriental patients with SLE. Ann Rheum Dis 1985;44:260-1.
127. ter Borg E, Horst G, Limburg P et al. C-reactive protein levels during exacerbations and infections in SLE: a prospective longitudinal study. J Rheumatol 1991;17:118.
128. Zein N, Ganuza C, Kushner I. Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum 1979;22:7-12.
129. D'Cruz DP. Systemic lupus erythematosus. Br Med J 2006;332:890-4.
130. Shmerling RH. Diagnostic tests for rheumatic disease: clinical utility revisited. South Med J 2005;98:704-11; quiz 712-3, 728. Review.